Daiichi Sankyo Mexico, a subsidiary of Daiichi Sankyo Company, has introduced antihypertensive franchise olmesartan medoxomil in Mexico under the name, Openvas.
The company has also unveiled Openvas Co, a combination preparation for use with a diuretic.
Openvas and Openvas Co are the first pharmaceuticals marketed by a Daiichi Sankyo Group company in Mexico.
With the marketing of both the agents, Daiichi Sankyo Mexico expects to contribute to treatment of hypertension in the region.
Daiichi Sankyo Mexico was established in 2011 to offer both new and established medicines in Mexico.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/daiichi-sankyo-introduces-antihypertensive-franchise-olmesartan-medoxomil-in-mexico-120612
